Celltrion’s ‘Remsima’ acquired the Australian approval

Celltrion announced on the 10^th that the company has acquired approval for Remsima from the Australian food and drug ministry, TGA(Therapeutic Goods Administration).

The TGA is expected to apply the same indication and health insurance benefit as the original drug on Remsima. The Australian TNF-Alpha inhibitor market is worth KRW 550 billion(approximately $460 million).

Australia is one of th...